NEW ANALYSIS: NAFTA 2.0 (U.S.-Mexico-Canada Agreement) Pharmaceutical Related Patent Provisions
The revised North American Free trade Agreement (NAFTA 2.0), rebranded by the Trump Administration as the U.S.-Mexico-Canada Agreement or USMCA, was signed last Friday during the G20 summit in Argentina. NAFTA 2.0 is an updated version of the nearly 25-year-old NAFTA, with significant and harmful changes to the intellectual property (IP) provisions, which build on the harmful TRIPS-plus standards in other U.S. free trade agreements since NAFTA 1.0.
Read More